3-(2-Methoxyethyl)-2,4(1H,3H)-Quinazolinedione
![]() |
- $367 - $918
- Product name: 3-(2-Methoxyethyl)-2,4(1H,3H)-Quinazolinedione
- CAS: 77093-97-1
- MF: C11H12N2O3
- MW: 220.22
- EINECS:-0
- MDL Number:MFCD16629931
- Synonyms:3-(2-Methoxyethyl)-2,4(1H,3H)-Quinazolinedione;3-(2-Methoxyethyl)quinazoline-2,4(1H,3H)-dione;2,4(1H,3H)-Quinazolinedione, 3-(2-methoxyethyl)-
4 prices
Selected condition:
Brand
- Alichem
- Chemenu
- Crysdot
Package
- 250mg
- 1g
- ManufacturerAlichem
- Product number77093971
- Product description3-(2-Methoxyethyl)quinazoline-2,4(1H,3H)-dione
- Packaging1g
- Price$908.82
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM216739
- Product description3-(2-Methoxyethyl)quinazoline-2,4(1H,3H)-dione 95%
- Packaging1g
- Price$858
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11059541
- Product description3-(2-Methoxyethyl)quinazoline-2,4(1H,3H)-dione 95+%
- Packaging250mg
- Price$367
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11059541
- Product description3-(2-Methoxyethyl)quinazoline-2,4(1H,3H)-dione 95+%
- Packaging1g
- Price$918
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Alichem | 77093971 | 3-(2-Methoxyethyl)quinazoline-2,4(1H,3H)-dione | 1g | $908.82 | 2021-12-16 | Buy |
Chemenu | CM216739 | 3-(2-Methoxyethyl)quinazoline-2,4(1H,3H)-dione 95% | 1g | $858 | 2021-12-16 | Buy |
Crysdot | CD11059541 | 3-(2-Methoxyethyl)quinazoline-2,4(1H,3H)-dione 95+% | 250mg | $367 | 2021-12-16 | Buy |
Crysdot | CD11059541 | 3-(2-Methoxyethyl)quinazoline-2,4(1H,3H)-dione 95+% | 1g | $918 | 2021-12-16 | Buy |
Properties
storage temp. :Sealed in dry,Room Temperature
Safety Information
Symbol(GHS): |
![]() |
|||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|